source
- Biotech firm Biogen secures Chinese approval for felzartamab in second-line multiple myelomaBiogen announced that its monoclonal antibody felzartamab has received regulatory clearance in China for use in patients with multiple myeloma who have already received first-line therapy. The app…
- Capricor to submit additional data to FDA after negative advisory committee vote on Duchenne therapyCapricor Therapeutics announced it will request the FDA to review new data and analyses for its experimental treatment for Duchenne muscular dystrophy. The move follows a recent negative vote from…